Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

76.24USD
25 Apr 2017
Change (% chg)

$1.63 (+2.18%)
Prev Close
$74.61
Open
$76.31
Day's High
$76.57
Day's Low
$75.81
Volume
785,494
Avg. Vol
608,225
52-wk High
$83.58
52-wk Low
$66.93

Latest Key Developments (Source: Significant Developments)

Novartis CEO says takeover prices have risen, focusing on early-stage targets
Tuesday, 25 Apr 2017 01:57am EDT 

April 25 (Reuters) - Novartis Ag :CEO Joe Jimenez says thinks with Cosentyx "we can hold our own" against lilly drug taltz.Says price of potential acquisitions has increased, prompting company to "go upstream" for early stage drug acquisitions.Jimenez says Entresto on track for the objectives for the year, expects growth quarter-by-quarter.Jimenez says timing of Novartis's involvement in Turkey campaign was unfortunate, but principle of supporting patients around the world remains, declined to comment on plans for campaign.  Full Article

Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine
Monday, 24 Apr 2017 04:30pm EDT 

April 24 (Reuters) - Amgen Inc ::Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine.Says co, Novartis agreed to combine capabilities to co-commercialize erenumab in U.S.; Amgen retains exclusive commercialization rights in Japan.Says Novartis gains exclusive rights to commercialize erenumab in Canada, retains existing commercialization rights in rest of the world.Says co will receive milestone payments from Novartis expected to begin in 2017; Novartis will share u.s. Commercialization costs with Amgen.Says co will book sales of erenumab in the U.S., and will pay a royalty to Novartis on net sales in the u.s..Says Novartis to book sales in rest of the world (excluding Japan), to pay co royalties on net sales in those countries; co to book sales in Japan.Says Novartis will assume agreed upon remaining global development costs up to a cap and share global development costs thereafter.  Full Article

EU Medicines Agency recommendations for April 2017
Friday, 21 Apr 2017 01:51pm EDT 

April 21 (Reuters) - EU Medicines Agency -:EU Medicines Agency recommendations for April 2017.EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia.Recommends approval of Sanofi SA and Regeneron's Kevzara (Sarilumab) for treatment of rheumatoid arthritis.Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug.Recommends approval of Pfizer's Besponsa for treatment of acute lymphoblastic leukaemia.Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug.Recommends approval of GMP-Orphan SA's Cuprior for treatment of Wilson's disease.Recommends approval of Almirall's Skilarence for treatment of psoriasis.Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia.  Full Article

Parvus Therapeutics announces license and collaboration agreement of its lead nanomedicine to treat type 1 diabetes
Wednesday, 19 Apr 2017 08:00am EDT 

April 19 (Reuters) - Novartis Ag :Parvus therapeutics announces exclusive worldwide license and collaboration agreement for development and commercialization of its lead nanomedicine to treat type 1 diabetes.Parvus therapeutics says has entered into a license and collaboration agreement with novartis for its lead navacim for treating type 1 diabetes.Parvus-Under terms,novartis receives exclusive, worldwide rights to use parvus' navacim technology to develop, commercialize products for treatment of type 1 diabetes.Parvus therapeutics - novartis will be responsible for clinical-stage development and commercialization activities.Parvus therapeutics says novartis has also made an equity investment in parvus.Parvus therapeutics - parvus has received an upfront payment and will receive research funding to support preclinical activities.  Full Article

Novartis expands trials for NASH via collaboration with Allergan
Tuesday, 18 Apr 2017 01:22am EDT 

April 18 (Reuters) - Novartis said:Novartis expands development programs for NASH through clinical collaboration with Allergan.Phase IIb clinical trial launched to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease.NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver, inflammation and fibrosis (scarring), and can eventually lead to cirrhosis and liver failure. NASH is a major cause of liver disease worldwide and the leading cause of liver transplants for people under 50 in the US. There are currently no approved treatments for NASH..Financial details of the transaction were not disclosed..  Full Article

Novartis' Cart-T Therapy CTl019 gets FDA breakthrough therapy designation
Tuesday, 18 Apr 2017 01:17am EDT 

April 18 (Reuters) - Novartis Ag :Novartis car-t cell therapy ctl019 receives FDA breakthrough therapy designation for treatment of adult patients with r/r DLBCL.Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation.  Full Article

Torrent Pharma says it had signed deals with Novartis AG to buy generic pharmaceutical products
Tuesday, 11 Apr 2017 09:13am EDT 

Torrent Pharmaceuticals Ltd : Torrent Pharmaceuticals clarifies on news item 'torrent close to buying women healthcare portfolio of Swiss pharma major Novartis' .Had executed certain agreements with Novartis AG to buy certain generic pharmaceutical products.  Full Article

Novartis to in-license ECF843 for ophthalmic indications
Thursday, 6 Apr 2017 01:20am EDT 

Novartis Ag : Novartis to strengthen research and development pipeline by in-licensing ECF843 for ophthalmic indications .Says exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe).  Full Article

Vectura says US licensee of group's partner Novartis AG launched Utibron Neohaler in US
Monday, 3 Apr 2017 11:56am EDT 

Vectura Group Plc : Sunovion Pharmaceuticals, US licensee of group's partner Novartis AG launched Utibron Neohaler in US .Sunovion confirmed it expect to launch Seebri in US during next twelve months.  Full Article

Novartis says drug combination Tafinlar + Mekinist receives EU approval
Monday, 3 Apr 2017 01:18am EDT 

Novartis Ag :Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF v600-positive advanced non-small cell lung cancer (NSCLC).  Full Article

More From Around the Web

Novartis to speed up bid for MS drug approval, changes target

ZURICH Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.